These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 7669684)

  • 1. Failure of Orgaran therapy in a patient with a previous heparin-induced thrombocytopenia syndrome.
    Tardy/Poncet B; Mahul P; Beraud AM; Favre JP; Tardy B; Guyotat D
    Br J Haematol; 1995 Aug; 90(4):969-70. PubMed ID: 7669684
    [No Abstract]   [Full Text] [Related]  

  • 2. [Danaparoid (orgaran) for continuous venovenous hemodiafiltration in a patient with heparin-induced thrombocytopenia].
    Christin F; Theissen-Laval O; Loeb JP
    Ann Fr Anesth Reanim; 1998; 17(1):82-3. PubMed ID: 9750692
    [No Abstract]   [Full Text] [Related]  

  • 3. [Value of orgaran in hemodialysis during heparin-induced thrombopenia].
    Lamriben L; Tiberghien F; Delacour JL; Floriot C; Wagschal G; Daoudal P; Ory JP
    Presse Med; 1996 Sep; 25(28):1303. PubMed ID: 8949796
    [No Abstract]   [Full Text] [Related]  

  • 4. Heparin-induced thrombocytopenia type II: successful use of Orgaran (ORG 10172) in intensive care patients.
    Burkhard-Meier U; Söhngen D; Schultheiss HP; Greinacher A; Schwartzkopff B; Vogt M; Heyll A; Schneider W
    Intensive Care Med; 1995 Jun; 21(6):542-3. PubMed ID: 7560499
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of heparin-induced thrombocytopenia.
    Peters FP
    J Thorac Cardiovasc Surg; 1997 Sep; 114(3):517-8. PubMed ID: 9305220
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical experiences with Danaparoid sodium. Measures to be taken in heparin-induced thrombocytopenia].
    Anaesthesist; 1998 Nov; 47(11 Suppl Massnahmen):1-4. PubMed ID: 9884734
    [No Abstract]   [Full Text] [Related]  

  • 7. The use of low dose Orgaran in heparin-induced thrombocytopenia associated with in vitro platelet aggregation at higher Orgaran concentrations.
    Hill GR; Hickton C; Henderson S; Patton WN
    Clin Lab Haematol; 1997 Jun; 19(2):155-7. PubMed ID: 9218159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiopulmonary bypass and heparin-induced thrombocytopenia: pitfalls of anticoagulation with danaparoid.
    Kanagasabay R; Unsworth-White MJ; Farnsworth G; Haxby EJ; Smith EE
    J Thorac Cardiovasc Surg; 2000 Aug; 120(2):428-9. PubMed ID: 10917979
    [No Abstract]   [Full Text] [Related]  

  • 9. Failure of danaparoid anticoagulation for cardiopulmonary bypass.
    Ariano RE; Bhattacharya SK; Moon M; Brownell LG
    J Thorac Cardiovasc Surg; 2000 Jan; 119(1):167-8. PubMed ID: 10612777
    [No Abstract]   [Full Text] [Related]  

  • 10. Orgaran during rotational atherectomy in the setting of heparin-induced thrombocytopenia.
    Hale LP; Smith K; Braden GA; Owen J
    Cathet Cardiovasc Diagn; 1998 Nov; 45(3):318-22. PubMed ID: 9829897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).
    Saxon BR; Black MD; Edgell D; Noel D; Leaker MT
    Ann Thorac Surg; 1999 Sep; 68(3):1076-8. PubMed ID: 10510017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of danaparoid during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia.
    Olin DA; Urdaneta F; Lobato EB
    J Cardiothorac Vasc Anesth; 2000 Dec; 14(6):707-9. PubMed ID: 11139115
    [No Abstract]   [Full Text] [Related]  

  • 13. Heparin-induced thrombocytopenia and antithrombotic therapy.
    Boon DM; Michiels JJ; Stibbe J; van Vliet HH; Kappers-Klunne MC
    Lancet; 1994 Nov; 344(8932):1296. PubMed ID: 7526097
    [No Abstract]   [Full Text] [Related]  

  • 14. [Anticoagulants in clinical practice].
    Boneu B
    Rev Prat; 1999 Oct; 49(15):1641-7. PubMed ID: 10581994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Extracorporeal circulation with danaparoid sodium for valve replacement in thrombocytopenia induced by type II heparin].
    Salmi L; Leroy-Matheron C; LeBesnerais P; Rosanval O; Duvaldestin P; Gouault-Heilmann M
    Ann Fr Anesth Reanim; 2001 Nov; 20(9):799-802. PubMed ID: 11759322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical experience with Danaparoid-sodium: measures to be taken in heparin-induced thrombocytopenia].
    Chirurg; 1998 Nov; 69(11 Suppl Massnahme):1-4. PubMed ID: 9853175
    [No Abstract]   [Full Text] [Related]  

  • 17. Heparin-induced thrombocytopenia (HIT): in vitro and in vivo cross-reactivity to danaparoid sodium and successful treatment with recombinant hirudin (lepirudin).
    Baumgärtel MW; Eichler P; Glöckner WM; Ranze O; Greinacher A
    Eur J Haematol; 2000 Aug; 65(2):148-9. PubMed ID: 10966178
    [No Abstract]   [Full Text] [Related]  

  • 18. Danaparoid sodium (Orgaran) in four children with heparin-induced thrombocytopenia type II.
    Zöhrer' B; Zenz W; Rettenbacher A; Covi P; Kurnik K; Kroll H; Grubbauer HM; Muntean W
    Acta Paediatr; 2001 Jul; 90(7):765-71. PubMed ID: 11519979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Danaparoid thromboprophylaxis in pregnant women with heparin-induced thrombocytopenia.
    Woo YL; Allard S; Cohen H; Letsky E; de Swiet M
    BJOG; 2002 Apr; 109(4):466-8. PubMed ID: 12013171
    [No Abstract]   [Full Text] [Related]  

  • 20. Management of heparin-induced thrombocytopenia during continuous renal replacement therapy.
    Davenport A
    Am J Kidney Dis; 1998 Oct; 32(4):E3. PubMed ID: 10074589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.